07:39 AM EDT, 08/18/2025 (MT Newswires) -- Traws Pharma ( TRAW ) said Monday it received approval from the Human Research Ethics Committee to proceed with a phase 2 study of ratutrelvir to treat patients with newly diagnosed COVID.

The first trial will allow the company to compare ratutrelvir with Pfizer's ( PFE ) Paxlovid. Traws Pharma ( TRAW ) said it will launch a second trial to evaluate the safety and efficacy of ratutrelvir in Paxlovid-ineligible patients.

The company expects to report the results of the studies by the end of 2025.

Traws Pharma ( TRAW ) shares were up 7.3% in recent premarket activity.